BioSpace News Archive

The standard physician sample pack of Allergan’s Taytulla birth control pills should have 24 pink capsules that contain hormones with four maroon capsules at the end of the package cycle that do not have hormones. However, 170,000 packages had four maroon placebos located at the beginning of the treatment cycle.

AstraZeneca’s add-on asthma treatment Fasenra has failed a second Phase III trial this month.

Purdue Pharmaceuticals has named a new head of corporate social responsibility as it continues to grapple with negative attention due to the rampant opioid crisis across the United States.

Roseanne Barr has courted controversy with comments concerning immigration, the Parkland school shooting, and various racist and anti-Semitic conspiracy theories. She later blamed these comments on her use of the sleep medication Ambien.

Novo Nordisk announced results from its second Phase IIIa clinical PIONEER 2 trial.

Florida-based TherapeuticsMD is feeling a bit vindicated this morning after the U.S. Food and Drug Administration approved its vaginal pain medication.

Over the last five years, AbbVie shares are up about 130 percent. It’s generally viewed as a volatile stock.

Allergan will sell off two non-core businesses following a strategic review of the company’s assets, according to multiple reports.

Collaboration to utilize Schrödinger’s advanced computation platform technology to accelerate discovery of immuno-oncology and other cancer biologics

The Series C Round led by Asahi Glass Co., Ltd. “AGC” includes participation from all prior investors (Phoenix Venture Partners, Oregon Venture Fund, WRF Capital, and Souther Co.) and new investors Columbia Ventures Corporation and GreenBridge.